Ascletis to Present ASC47 Weight Loss Drug at European Congress

Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.

Ascletis Pharma Inc. announced that it will present findings on ASC47, its adipose-targeted, muscle-preserving weight loss drug candidate, at the 32nd European Congress on Obesity. The presentations will showcase the drug’s potential in obesity treatment, highlighting significant weight loss and muscle preservation in preliminary studies. This development could enhance Ascletis’s position in the obesity treatment market, potentially impacting stakeholders by demonstrating the efficacy of ASC47 in clinical settings.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs, particularly in the field of obesity management. The company specializes in creating adipose-targeted, muscle-preserving weight loss drug candidates, with a market focus on addressing obesity and related conditions.

YTD Price Performance: 117.61%

Average Trading Volume: 7,664,032

Technical Sentiment Signal: Sell

Current Market Cap: HK$6.35B

For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.